YmAbs Therapeutics, Inc. (YMAB) Q4 2019 Earnings Call Transcript [The Motley Fool]
Y-mAbs Therapeutics, Inc. (YMAB)
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm
Check Earnings Report
Company Research
Source: The Motley Fool
Image source: The Motley Fool. YmAbs Therapeutics, Inc. ( NASDAQ:YMAB Mar 2, 2020 4:30 p.m. ET Contents: : Operator Greetings, and welcome to the Y-mAbs Full Year 209 Earnings Conference Call. [Operator Instructions] As a remainder this conference is being recorded. It is now my pleasure to introduce your host Thomas Gad, Chairman and President. Please go ahead. Chairman, Founder, President, and Head of Business Development & Strategy. Thank you, Ashley. Good afternoon everyone and thank you for joining us on this particular day. So 209 was the year that we believe we made significant progress on our strategy and took steps that position us very well for 2020 as we work to complete two BLA submissions, and prepare for two potential product launches, while significantly expanding our clinical activities. We ended 209 with $207 million in cash. And as you know in late October, we completed a secondary offering led by Morgan Stanley, JPMorgan and BAML, in which we raised approximately
Show less
Read more
Impact Snapshot
Event Time:
YMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
YMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
YMAB alerts
High impacting Y-mAbs Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
YMAB
News
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $23.00 price target on the stock.MarketBeat
- Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]Yahoo! Finance
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.MarketBeat
- Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... [Yahoo! Finance]Yahoo! Finance
- Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewswire
YMAB
Earnings
- 11/8/24 - Miss
YMAB
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/8/24 - Form 10-Q
- YMAB's page on the SEC website